< All Topics

Elevated ccl19 after completion of therapy for acute lyme disease identifies patients at risk for development of post-treatment lyme disease syndrome who will benefit from further antibiotic therapy


The Johns Hopkins University. 2016.



John N. Aucott, Mark J. Soloski

Quansys Products Used:

Human Chemokine (4-Plex)


The present invention relates to the field of Lyme disease. More specifically, the present invention provides methods and composition useful for the treatment of Lyme disease. In one aspect, the present invention provides compositions and methods for treating a patient at risk for or likely to develop post-treatment Lyme disease syndrome (PTLDS). In certain embodiments, the patient is already undergoing a first course of antibiotic treatment for Lyme disease. In a specific embodiment, a method comprises the step of prescribing or administering a second course of antibiotic treatment to a patient who is determined to have an increased level of CCL19 as compared to a control after completing a first course of antibiotics for Lyme disease.

Previous Continuous exposure to non-lethal doses of sodium iodate induces retinal pigment epithelial cell dysfunction
Next Development of Electrochemical Immunosensors towards Point-of-care Cancer Diagnostics: Clinically Relevant Studies